Efficacy and safety of acotiamide in esophagogastric junction outflow obstruction: a placebo-controlled phase II trial.

BACKGROUND

Currently, there are no established treatments for esophagogastric junction outflow obstruction (EGJOO). In this study, we evaluated the efficacy and safety of acotiamide for EGJOO by targeting impaired lower esophageal sphincter (LES) function.

METHODS

This investigator-initiated, multicenter, randomized, double-blind, placebo-controlled phase II trial enrolled 35 patients with EGJOO between December 2021 and December 2023. Patients were randomized to receive either placebo (n = 11) or acotiamide (300 mg/day, n = 12; 600 mg/day, n = 12) for 4 weeks (placebo-controlled period). Subsequently, all patients received 600 mg/day acotiamide for an additional 4 weeks (open-label period).

RESULTS

As a primary endpoint, during the placebo-controlled period, the improvement rate of food-sticking symptoms in the chest was 12.5% and 0.0% in the acotiamide and placebo groups, respectively (p = 0.3092). In terms of secondary endpoints, the integrated relaxation pressure (IRP) normalization rate was significantly higher in the acotiamide group (41.7%) than in the placebo group (0.0%) (p = 0.0107). No other secondary endpoints showed significant differences between the groups. Regarding the exploratory endpoints, during the open-label period, among the 24 patients treated with ≥ 300 mg/day of acotiamide for 8 weeks, the improvement rate of food-sticking symptoms in the chest increased to 37.5%, and the IRP normalization rate rose to 54.2%.

CONCLUSIONS

Acotiamide is effective in normalizing impaired LES relaxation in patients with EGJOO and may improve food-sticking symptoms in the chest.

CLINICAL TRIAL REGISTRATION: Japan Registry of Clinical Trials ( https://jrct.mhlw.go.jp/en-top ); registration number jRCT2071210072.